Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial.

@article{Serebruany2006ValsartanIP,
  title={Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial.},
  author={Victor L Serebruany and Alex N. Pokov and Alex I. Malinin and Christopher M. O'connor and Deepak L. Bhatt and Jean-François Tanguay and David C. Sane and Charles H. Hennekens},
  journal={American heart journal},
  year={2006},
  volume={151 1},
  pages={
          92-9
        }
}
BACKGROUND Previous in vitro studies have suggested that valsartan produces significant inhibition of human platelets, probably targeting angiotensin I platelet receptors. To test whether valsartan inhibits platelet activity in mild to moderate hypertensives we conducted the randomized Valsartan Inhibits Platelets (VIP) trial. METHODS AND RESULTS Seventy-five patients with mild to moderate hypertension were randomized to valsartan 80 (n = 25), valsartan 160 (n = 29), or valsartan 320 mg/d (n… Expand
Antiplatelet Properties of Escitalopram in Patients with the Metabolic Syndrome: A Dose-Ranging In Vitro Study
TLDR
The in vitro antiplatelet characteristics of ESC in patients with the metabolic syndrome are similar to those in healthy volunteers, however, higher ESC doses are required to induce equally potent platelet inhibition. Expand
Effect of Aliskiren and Valsartan Combination Versus Aliskiren Monotherapy on Hemostatic Biomarkers in Hypertensive Diabetics: Aliskiren and Valsartan Impact in Diabetics Pilot Trial
TLDR
Randomized data were generated on top of low-dose daily aspirin, supporting extra benefit for combination use of angiotensin receptor blockers and renin inhibitors in high-risk diabetic population and suggesting that previous data probably represent a laboratory artifact. Expand
Effects of aliskiren, a renin inhibitor, on biomarkers of platelet activity, coagulation and fibrinolysis in subjects with multiple risk factors for vascular disease
TLDR
Higher aliskiren doses were associated with more profound biomarker changes, but they are likely not to be clinically relevant since they show diverging trends, and considering the 2- to 4-fold safety margin. Expand
Antiplatelet Activity of the Antihypertensive Agent Losartan In Vivo Characterization
Objective: The purpose of this study is to investigate the potential in vivo antiplatelet and thromboprotective properties of the antihypertensive drug losartan in mice. Methods: Aggregometry studiesExpand
Characterization of the In Vivo Antiplatelet Activity of the Antihypertensive Agent Losartan
TLDR
Losartan’s chemistry may provide a “blueprint” for designing or repurposing novel derivatives which may have the potential to serve as an antiplatelet and thromboprotective agents but are deprived of the usually concomitant bleeding adverse effects. Expand
Early Impact of Prescription Omega-3 Fatty Acids on Platelet Biomarkers in Patients with Coronary Artery Disease and Hypertriglyceridemia
TLDR
Independently of the dose and already at 1 week, short-term therapy with PO-3A provided a modest reduction of platelet activity biomarkers, despite concomitant aspirin and statin therapy, when compared to a placebo. Expand
Drugs that affect platelet function.
  • R. Scharf
  • Medicine
  • Seminars in thrombosis and hemostasis
  • 2012
TLDR
A review of the large variety of agents that have not been designed for antiplatelet therapy but nevertheless interfere with platelet reactivity or induce platelet inhibition is provided. Expand
Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors
TLDR
Broad use of statins, angiotensin receptor blockers and selective serotonin reuptake inhibitors may be in part responsible for the lack of impressive results with the antiplatelet therapy because each of these drug classes per se inhibits platelets. Expand
Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease
TLDR
Patients with metabolic syndrome exhibited a higher degree of platelet activation than subjects with conventional risk factors for vascular disease, and applying adequate antiplatelet strategies may reduce the risk of acute thrombotic events in these patients. Expand
Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation.
TLDR
Given the pro-inflammatory effects of Ang II and aldosterone, agents that interfere with the components of RAAS, such as ACE inhibitors, Angiotensin Receptor Blockers (ARBs), and mineralocorticoid receptor antagonists represent logical therapeutic tools to reduce vascular inflammation and cardiovascular risk. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 39 REFERENCES
Effects of Valsartan and Valeryl 4-Hydroxy Valsartan on Human Platelets: A Possible Additional Mechanism for Clinical Benefits
TLDR
Valsartan and 4VHV exhibited significant in vitro inhibition of human platelets, and their antiplatelet properties, especially more potent activity of the metabolite appear to be independent of those of other antiplatelets. Expand
Inhibition of Platelet Activation in Stroke-Prone Spontaneously Hypertensive Rats: Comparison of Losartan, Candesartan, and Valsartan
TLDR
The antiplatelet effect of losartan does not appear to be related to the level of blood pressure reduction and in ex vivo experiments,Losartan significantly reduced the binding of the radiolabeled TxA2 agonist U46619 to platelets obtained from SHRSP in a dose-dependent manner. Expand
Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
TLDR
Results suggest that some AT-1-receptor antagonists reduce TxA2-dependent activation independent of Ang II involvement, and Losartan or irbesartan reduced the binding of [3H]-U46619 to platelets, an effect that was observed with lower ability with the other AT- 1 antagonists. Expand
A single (investigator)-blind randomised control trial comparing the effects of quinapril and nifedipine on platelet function in patients with mild to moderate hypertension
TLDR
The results indicate that the ACE inhibitor, quinapril, has a beneficial effect on platelet function unlike the calcium channel blocker, nifedipine. Expand
Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition.
TLDR
The results show that platelet activation was evident only in CHF rats, which was completely rescued to basal levels by combination therapy, and increased nitric oxide bioavailability can only partially explain the reduced plateletactivation by eplerenone and ACE inhibition. Expand
Angiotensin II AT(1) receptor antagonists and platelet activation.
TLDR
In vivo administration of losartan decreases P-selectin expression in platelets obtained from stroke-prone spontaneously hypertensive rats, suggesting that the structural requirements necessary to antagonize the TXA2/PGH2 platelet receptor may be different from those involved in AT1 receptor antagonism. Expand
Platelet activation during angiotensin II infusion in healthy volunteers
TLDR
Angiotensin II has mild platelet‐activating effects in vivo and also enhances coagulation and markers of platelet secretion are significantly increased, whereas markers of Platelet aggregability are less affected. Expand
Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy.
TLDR
The ARB valsartan has BP-independent effects on LVH, ROS formation by monocytes, and CRP in hypertensive patients with LVH in a cross-sectional and prospective study. Expand
Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
TLDR
The dual antagonistic actions of irbesartan by acting at both the AT(1) and TxA(2) receptors in blood vessels and platelets may overall enhance its therapeutic profile in the treatment of hypertension, atherosclerosis, and arterial thrombosis. Expand
Angiotensin II AT1 Receptor Antagonists Inhibit Platelet Adhesion and Aggregation by Nitric Oxide Release
TLDR
A crucial role of NO is indicated in the arterial antithrombotic effects of angiotensin II AT1-receptor antagonist–stimulated NO release in platelets and endothelial cells. Expand
...
1
2
3
4
...